參考文獻 |
1. Liyanage T.,et al, Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015 May 16;385(9981):1975-82.
2. Morelle J, Devuyst O, Water and solute transport across the peritoneal membrane. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):434-43.
3. Morelle J.,et al, Mechanisms of Crystalloid versus Colloid Osmosis across the Peritoneal Membrane. J Am Soc Nephrol. 2018 Jul;29(7):1875-1886.
4. Li PK., et al, Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017 Feb;13(2):90-103.
5. Mehrotra R.,et al, The Current State of Peritoneal Dialysis. J Am Soc Nephrol. 2016 Nov;27(11):3238-3252.
6. Ron Pisoni., et al, Chapter 11: International Comparisons. American Journal of Kidney Diseases, 2019 Mar;71(3), S461–S500.
7. Davies SJ, Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int. 2004 Dec;66(6):2437-45.
8. Aroeira LS., et al, Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol.2007 Jul;18(7):2004-13.
9. Wang Y., et al, Peritoneal fibrosis and epigenetic modulation. Perit Dial Int.2021 Mar;41(2):168-178.
10. De Vriese AS., et al, Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephro.2003 Aug;14(8):2109-2118.
11. Tomino Y, Mechanisms and interventions in peritoneal fibrosis. Clin Exp Nephrol. 2012 Feb;16(1):109-14.
12. Honda K., et.al, Peritoneal Dialysis: Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol.2008 May;3(3):720-8.
13. Jagirdar RM., et.al, Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options. Int J Mol Sci. 2019 Nov; 20(22): 5765.
14. Devuyst O., et.al, The pathophysiology of the peritoneal membrane. J Am Soc Nephro.2010 Jul;21(7):1077-85.
15. Tseng CC., et.al, Incidence and outcomes of encapsulating peritoneal sclerosis (EPS) and factors associated with severe EPS. PLoS One.2018 Jan 2;13(1): e0190079.
16. Danford CJ, Lin SC, Smith MP, Wolf JL. Encapsulating peritoneal sclerosis. World J Gastroenterol. 2018 Jul 28;24(28):3101-3111.
17. Korte MR., et.al, Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant.2011 Feb;26(2):691-7.
18. Kawanishi H., et.al, Surgical techniques for prevention of recurrence after total enterolysis in encapsulating peritoneal sclerosis. Adv Perit Dial.2008;24:51-5.
19. Moinuddin Z., et. al, Encapsulating peritoneal sclerosis—a rare but devastating peritoneal disease. Front Physiol.2014; 5: 470.
20. Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet.2016;17:719–732.
21. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007 Jun;9(6):654-9.
22. Vanni I, Alama A, Grossi F, Dal Bello MG, Coco S. Exosomes: a new horizon in lung cancer. Drug Discov Today. 2017 Jun;22(6):927-936.
23. Massagué J, TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30.
24. Derynck R, Weinberg RA, EMT and Cancer: More Than Meets the Eye. Dev Cell. 2019 May 6;49(3):313-316.
25. Thiery JP, Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002 Jun;2(6):442-54.
26. Derynck R, Budi EH, Specificity, versatility, and control of TGF-β family signaling. Sci Signal. 2019 Feb 26;12(570): eaav5183.
27. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J, Mechanism of activation of the TGF-beta receptor. Nature. 1994 Aug 4;370(6488):341-7.
28. Tsubakihara Y, Moustakas A, Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor β. Int J Mol Sci. 2018 Nov 20;19(11):3672.
29. Hua W, Ten Dijke P, Kostidis S, Giera M, Hornsveld M, TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cell Mol Life Sci. 2020 Jun;77(11):2103-2123.
30. Derynck R, Zhang YE, Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature. 2003 Oct 9;425(6958):577-84.
31. Xu W, Yang Z, Lu N, A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. 2015;9(4):317-24.
32. Xue G., et.al, Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating crosstalk between PI3K/Akt and TGF-β signaling axes. Cancer Discov. 2012 Mar;2(3):248-59.
33. Ambros V, A hierarchy of regulatory genes controls a larva-to-adult developmental switch in C. elegans. Cell. 1989 Apr 7;57(1):49-57.
34. Lee RC, Feinbaum RL, Ambros V, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993 Dec 3;75(5):843-54.
35. Ruvkun G, Giusto J, The Caenorhabditis elegans heterochronic gene lin-14 encodes a nuclear protein that forms a temporal developmental switch. Nature. 1989 Mar 23;338(6213):313-9.
36. Ambros V. The functions of animal microRNAs. Nature. 2004 Sep 16;431(7006):350-5.
37. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004 Jan 23;116(2):281-97.
38. Lee, Y., et.al, MicroRNA genes are transcribed by RNA polymerase II. EMBO J.2004 Oct 13;23(20):4051-60.
39. Han.J. et.al, The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev.2004 Dec 15;18(24):3016-27.
40. Yi, R., et.al, Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev.2003 Dec 15;17(24):3011-6.
41. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001 Jan 18;409(6818):363-6.
42. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011 Feb;12(2):99-110.
43. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 2004 Mar 1;18(5):504-11.
44. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005 Jan 14;120(1):15-20.
45. Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood. 2006 Dec 1;108(12):3646-53.
46. Stahlhut C, Slack FJ. MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med. 2013 Dec 30;5(12):111.
47. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010 Oct;101(10):2087-92.
48. Wang Y, Shi Y, Tao M, Zhuang S, Liu N. Peritoneal fibrosis and epigenetic modulation. Perit Dial Int. 2021 Mar;41(2):168-178.
49. Li J., et al, HIF1A and VEGF regulate each other by competing endogenous RNA mechanism and involve in the pathogenesis of peritoneal fibrosis. Pathol Res Pract. 2019 Apr;215(4):644-652.
50. Wang W., et al, CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7. J Cell Mol Med.2019 Aug; 23(8): 5486–5496.
51. Yu F., et al, MicroRNA-17-5p-activated Wnt/β-catenin pathway contributes to the progression of liver fibrosis. Oncotarget. 2016 Jan 5;7(1):81-93.
52. Chen X., et al, MiR-17-5p downregulation alleviates apoptosis and fibrosis in high glucose-induced human mesangial cells through inactivation of Wnt/β-catenin signaling by targeting KIF23. Environ Toxicol. 2021 Aug;36(8):1702-1712.
53. Zhao X., et al, miR-17-5p promotes proliferation and epithelial-mesenchymal transition in human osteosarcoma cells by targeting SRC kinase signaling inhibitor 1. J Cell Biochem. 2019 Apr;120(4):5495-5504.
54. Bao C., et al, Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial-mesenchymal transition via miR-17-5p/PTEN/Akt pathway. J Cancer. 2021 Jan 1;12(1):76-88.
55. Zhou B., et al, MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1. Biomed Pharmacother. 2017 Mar; 87:412-418.
56. Han X., et al, Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1/microRNA-202-3p/periostin axis modulates invasion and epithelial-mesenchymal transition in human cervical cancer. J Cell Physiol. 2019 Aug;234(8):14170-14180.
57. Wu HY, Wu JL, Ni ZL. Overexpression of microRNA-202-3p protects against myocardial ischemia-reperfusion injury through activation of TGF-β1/Smads signaling pathway by targeting TRPM6. Cell Cycle. 2019 Mar;18(5):621-637.
58. Song Q., et al, miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res. 2014 Jun 1;74(11):3031-42.
59. Li F., et al, Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice. J Cell Mol Med. 2014 Jun;18(6):966-74.
60. Chouri E., et al, Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. J Autoimmun. 2018 May; 89:162-170.
61. Huang G., et al, Downregulation of miR 483 5p inhibits TGF β1 induced EMT by targeting RhoGDI1 in pulmonary fibrosis. Mol Med Rep. 2021 Jul;24(1):538.
62. Liu D., et al, HNRNPA1-mediated exosomal sorting of miR-483-5p out of renal tubular epithelial cells promotes the progression of diabetic nephropathy-induced renal interstitial fibrosis. Cell Death Dis. 2021 Mar 10;12(3):255.
63. Zhang Q, Wang P, Fang X, Lin F, Fang J, Xiong C, Collagen gel contraction assays: From modelling wound healing to quantifying cellular interactions with three-dimensional extracellular matrices. Eur J Cell Biol. 2022 Jun-Aug;101(3):151253.
64. Bonomini M., et al, How to Improve the Biocompatibility of Peritoneal Dialysis Solutions (without Jeopardizing the Patient′s Health). Int J Mol Sci. 2021 Jul 26;22(15):7955.
65. Li L., et al, Inhibiting core fucosylation attenuates glucose-induced peritoneal fibrosis in rats. Kidney Int. 2018 Jun;93(6):1384-1396.
66. Wang AY, et al, 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report. Kidney Int Rep. 2019 Sep 23;4(11):1523-1537.
67. Kim TW, et al, MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer. Br J Cancer. 2020 Sep;123(7):1123-1130.
|